FDA Approves Zevaskyn, First Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

The Food and Drug Administration (FDA) has approved Zevaskyn, a gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). Zevaskyn represents the first gene therapy approved for this condition. The therapy aims to address wound healing and pain management in patients with RDEB. The FDA’s approval of Zevaskyn signifies a new treatment option for individuals suffering from RDEB, a rare genetic disorder characterized by fragile skin and chronic wounds. The gene therapy is designed to modify the patient’s cells to promote improved wound healing capabilities. The medical community anticipates Zevaskyn to provide a potential pathway for effective pain relief for RDEB patients.

Newsflash | Powered by GeneOnline AI
Date: April 29, 2025

Author

Mark Chiang